Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2050 Prototype · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Regimen A: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions. Regimen B: Participants will receive Dose C ALXN2050 MR Prototype Tablet orally under fasted conditions. Optional Regimens C, D, E, and F |
| Cohort 2 | EXPERIMENTAL | Regimen G: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions. Regimen H: Participants will receive Dose C ALXN2050 MR Prototype Mini-Tablet orally under fasted conditions. Optional Regimens: I, J, K, and L |
| Name | Type | Description |
|---|---|---|
| ALXN2050 MR Prototype Tablet | DRUG | Participants will receive various doses of the MR Prototype Tablet orally. |
| ALXN2050 Immediate Release (IR) Tablet | DRUG | Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally. |
| ALXN2050 MR Prototype Mini-Tablet | DRUG | Participants will receive various doses of the MR Prototype Mini-Tablet orally. |
Inclusion Criteria: * Healthy males or non-pregnant, non-lactating healthy females. * Participants who are overtly healthy as determined by medical evaluation including medical history, physical or neurological examination, vital signs, 12-lead ECG, screening clinical laboratory profiles (hematolog...
ALXN2050 Prototype is an investigational small molecule being developed by AstraZeneca PLC (AZN). It is currently in Phase 1 clinical development. The drug has been studied in healthy adult participants, and one clinical trial has been completed.
ALXN2050 Prototype is being studied for use in healthy participants. It is an investigational drug in Phase 1 clinical development, and no approved indications have been established. The completed trial focused on healthy adult volunteers.
ALXN2050 Prototype is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical research on this investigational small molecule drug.
ALXN2050 Prototype is in Phase 1 clinical development. It is an investigational drug and has not been approved. One Phase 1 clinical trial involving the drug has been completed.
ALXN2050 Prototype has been studied in clinical trial NCT05780645, titled "A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants." This Phase 1 trial was completed in the United Kingdom.
ALXN2050 Prototype is a modified release prototype formulation of ALXN2050. The clinical trial NCT05780645 compared the pharmacokinetic profile of ALXN2050 modified release prototype formulations with an immediate release reference tablet in healthy adult participants.